Literature DB >> 9856774

Effect of matrix metalloproteinases activity on outflow in perfused human organ culture.

J M Bradley1, J Vranka, C M Colvis, D M Conger, J P Alexander, A S Fisk, J R Samples, T S Acott.   

Abstract

PURPOSE: To test the hypothesis that extracellular matrix turnover, mediated by the matrix metalloproteinases, modulates aqueous humor outflow facility in a human outflow model.
METHODS: Matrix metalloproteinase activity was manipulated and outflow facility evaluated using perfused human anterior segment organ culture. Purified matrix metalloproteinases, tissue inhibitors of metalloproteinases (TIMPs), and several families of synthetic inhibitors of matrix metalloproteinases were added to the perfusion medium. Matrix metalloproteinase expression was increased by adding recombinant interleukin (IL)-1alpha. Kinetic inhibition analysis was conducted for stromelysin, gelatinase A, and gelatinase B with the various inhibitors. Live-dead staining was used to evaluate culture viability.
RESULTS: Increasing metalloproteinase activity, by adding purified metalloproteinases or by inducing their expression by IL-1alpha treatment, increased outflow facility. Inhibition of endogenous trabecular metalloproteinase activity using TIMP or several families of synthetic metalloproteinase inhibitors reduced outflow rates. The elevation and the reduction of outflow rates were reversible, with changes requiring 1 to 3 days. Kinetic enzyme inhibition analysis produced 50% inhibitory concentration values for these inhibitors that were compatible with the concentration ranges for outflow inhibition. CONCLUSIONS. The ability of several specific matrix metalloproteinase inhibitors to reduce outflow facility implies that endogenous extracellular matrix turnover by these enzymes was required for the maintenance of trabecular outflow resistance, at least in this human culture model. These observations provide support for the hypothesis that controlled extracellular matrix turnover is important in the regulation of aqueous humor outflow facility.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9856774

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  137 in total

Review 1.  Mechanisms of ATP release, the enabling step in purinergic dynamics.

Authors:  Ang Li; Juni Banerjee; Chi Ting Leung; Kim Peterson-Yantorno; W Daniel Stamer; Mortimer M Civan
Journal:  Cell Physiol Biochem       Date:  2011-12-16

Review 2.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

3.  The Effect of Cumulative Dissipated Energy on Changes in Intraocular Pressure After Uncomplicated Cataract Surgery by Phacoemulsification.

Authors:  Roland Y Lee; Rebecca I Chen; Toshimitsu Kasuga; Qi N Cui; Travis C Porco; Shan C Lin
Journal:  J Glaucoma       Date:  2016-07       Impact factor: 2.503

Review 4.  'What controls aqueous humour outflow resistance?'.

Authors:  Mark Johnson
Journal:  Exp Eye Res       Date:  2006-01-04       Impact factor: 3.467

Review 5.  Extracellular matrix in the trabecular meshwork.

Authors:  Ted S Acott; Mary J Kelley
Journal:  Exp Eye Res       Date:  2008-01-25       Impact factor: 3.467

6.  Individual molecular response to elevated intraocular pressure in perfused postmortem human eyes.

Authors:  Núria Comes; Teresa Borrás
Journal:  Physiol Genomics       Date:  2009-04-28       Impact factor: 3.107

Review 7.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

8.  Latanoprost-induced changes in rat intraocular pressure: direct or indirect?

Authors:  Shahid Husain; Phillip W Yates; Craig E Crosson
Journal:  J Ocul Pharmacol Ther       Date:  2008-08       Impact factor: 2.671

9.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

10.  Secreted protein acidic and rich in cysteine (SPARC)-null mice exhibit more uniform outflow.

Authors:  Swarup S Swaminathan; Dong-Jin Oh; Min Hyung Kang; Ruiyi Ren; Rui Jin; Haiyan Gong; Douglas J Rhee
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-21       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.